MAIA Biotechnology

MAIAPhase 3

MAIA Biotechnology is focused on researching, developing, and delivering innovative medicines for cancer treatment, with a core platform centered on telomere targeting. The company's lead candidate, ateganosine (THIO), represents a novel approach that combines telomere disruption with immune system activation. MAIA is a publicly traded company (NYSE American: MAIA) advancing its pipeline of second-generation telomere-targeting agents.

Market Cap

$85.6M

Focus

RNA & Gene Therapy

MAIA · Stock Price

USD 1.463.00 (-67.26%)

Historical price data

AI Company Overview

Technology Platform

Telomere-targeting immunotherapies combining telomere disruption with immune system activation for cancer treatment.

Pipeline Snapshot

3 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine al...	Carcinoma, Non-Small -Cell Lung	Phase 3
6-Thio-2'-Deoxyguanosine + Cemiplimab	Carcinoma, Non-Small-Cell Lung	Phase 2
ateganosine + Cadonilimab	Resectable Hepatocellular Carcinoma	Phase 1

Opportunities

The telomere-targeting platform represents a novel approach in oncology with potential across multiple cancer types.

Successful development of THIO could validate the mechanism and create opportunities for combination therapies and expanded indications.

The immuno-oncology component may synergize with existing cancer immunotherapies.

Risk Factors

Clinical development risks are significant for novel mechanisms like telomere targeting.

Financial sustainability depends on successful capital raises in volatile markets.

Competition in oncology is intense with many novel approaches in development.

Competitive Landscape

MAIA faces competition from both large pharmaceutical companies with broad oncology portfolios and smaller biotechs developing novel cancer therapies. Differentiation depends on demonstrating clinical advantages of its dual-mechanism telomere-targeting approach over existing standards of care and emerging therapies.